AR069847A1 - Composiciones farmaceuticas que contienen, por lo menos, un ingrediente activo proteinico protegido contra las enzimas digestivas - Google Patents

Composiciones farmaceuticas que contienen, por lo menos, un ingrediente activo proteinico protegido contra las enzimas digestivas

Info

Publication number
AR069847A1
AR069847A1 ARP080105568A ARP080105568A AR069847A1 AR 069847 A1 AR069847 A1 AR 069847A1 AR P080105568 A ARP080105568 A AR P080105568A AR P080105568 A ARP080105568 A AR P080105568A AR 069847 A1 AR069847 A1 AR 069847A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
active ingredient
digestive enzymes
proteinal
protected
Prior art date
Application number
ARP080105568A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Jacques Serrano
Original Assignee
Bennis Farid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bennis Farid filed Critical Bennis Farid
Publication of AR069847A1 publication Critical patent/AR069847A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ARP080105568A 2007-12-19 2008-12-19 Composiciones farmaceuticas que contienen, por lo menos, un ingrediente activo proteinico protegido contra las enzimas digestivas AR069847A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0759971A FR2925333B1 (fr) 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Publications (1)

Publication Number Publication Date
AR069847A1 true AR069847A1 (es) 2010-02-24

Family

ID=39671377

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105568A AR069847A1 (es) 2007-12-19 2008-12-19 Composiciones farmaceuticas que contienen, por lo menos, un ingrediente activo proteinico protegido contra las enzimas digestivas

Country Status (18)

Country Link
US (1) US8309123B2 (enExample)
EP (1) EP2234598B1 (enExample)
JP (1) JP5676272B2 (enExample)
KR (2) KR20150132887A (enExample)
CN (1) CN101917967B (enExample)
AP (1) AP3573A (enExample)
AR (1) AR069847A1 (enExample)
AU (1) AU2008345474B2 (enExample)
BR (1) BRPI0821373B8 (enExample)
CA (1) CA2709899C (enExample)
EA (1) EA023107B1 (enExample)
FR (1) FR2925333B1 (enExample)
IL (1) IL206364A (enExample)
MA (1) MA31927B1 (enExample)
MX (1) MX2010006927A (enExample)
TN (1) TN2010000290A1 (enExample)
TW (1) TWI461226B (enExample)
WO (1) WO2009083686A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
RU2016147009A (ru) 2014-05-01 2018-06-04 Сан Фармасьютикал Индастриз Лимитед Композиции с пролонгированным высвобождением в виде суспензии
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
CA2956902A1 (en) 2014-07-30 2016-02-04 Sun Pharmaceutical Industries Limited Dual-chamber pack
WO2016071756A1 (en) * 2014-11-04 2016-05-12 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
FR3120189B1 (fr) * 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE36225B1 (en) 1971-01-28 1976-09-15 Nat Res Dev Improvements relating to insulin derivatives
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
WO1985005029A1 (en) 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
US4693433A (en) * 1986-06-06 1987-09-15 Merrill David Martin Unwind stand for web rolls
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
EP0781142A4 (en) * 1994-09-01 2003-04-09 Allied Medical Res Associates Compositions and methods for delivery of polypeptides
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
CA2306024C (en) * 1997-10-01 2011-04-26 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6531648B1 (en) * 1998-12-17 2003-03-11 Syngenta Participations Ag Grain processing method and transgenic plants useful therein
PT1031347E (pt) * 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US6531112B2 (en) * 2000-05-15 2003-03-11 Delrx Pharmaceutical Corporation Formulations for administering calcitonin and processes for preparing the same
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
GB0119859D0 (en) * 2001-08-15 2001-10-10 Qinetiq Ltd Eye tracking system
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
EP1765406A4 (en) * 2004-05-21 2012-11-28 Mediplex Corp ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS
WO2006014673A2 (en) * 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
AU2006249480A1 (en) 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
US20090098205A1 (en) * 2005-09-15 2009-04-16 Council Of Scientife & Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
EP1957113A4 (en) * 2005-11-21 2011-11-09 Medivas Llc POLYMER PARTICLES FOR THE OUTPUT OF MACROMOLECULES AND METHOD OF APPLICATION THEREFOR
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin

Also Published As

Publication number Publication date
CA2709899C (fr) 2018-01-16
MA31927B1 (fr) 2010-12-01
BRPI0821373B1 (pt) 2020-04-22
AP3573A (en) 2016-02-08
WO2009083686A9 (fr) 2009-10-15
US8309123B2 (en) 2012-11-13
HK1146386A1 (en) 2011-06-03
CA2709899A1 (fr) 2009-07-09
CN101917967B (zh) 2013-05-22
AU2008345474A1 (en) 2009-07-09
BRPI0821373B8 (pt) 2021-05-25
KR20150132887A (ko) 2015-11-26
KR101592609B1 (ko) 2016-02-05
MX2010006927A (es) 2010-12-06
EP2234598B1 (fr) 2025-11-19
FR2925333A1 (fr) 2009-06-26
AU2008345474B2 (en) 2014-07-31
EA201070746A1 (ru) 2011-02-28
JP2011506587A (ja) 2011-03-03
BRPI0821373A2 (pt) 2015-06-16
TW200940107A (en) 2009-10-01
TWI461226B (zh) 2014-11-21
IL206364A (en) 2016-12-29
TN2010000290A1 (fr) 2011-11-11
EP2234598A1 (fr) 2010-10-06
WO2009083686A1 (fr) 2009-07-09
IL206364A0 (en) 2010-12-30
JP5676272B2 (ja) 2015-02-25
CN101917967A (zh) 2010-12-15
AP2010005298A0 (en) 2010-06-30
US20090176691A1 (en) 2009-07-09
KR20100095449A (ko) 2010-08-30
FR2925333B1 (fr) 2012-04-13
EA023107B1 (ru) 2016-04-29

Similar Documents

Publication Publication Date Title
AR069847A1 (es) Composiciones farmaceuticas que contienen, por lo menos, un ingrediente activo proteinico protegido contra las enzimas digestivas
PH12021551279A1 (en) Modified amine lipids
PE20110302A1 (es) Formulacion farmaceutica de un anticuerpo contra p-selectina
PH12021550701A1 (en) Ionizable amine lipids
TR200801337T1 (tr) Suda zayıf çözülebilen farmasötik ajanlar ve antimikrobiyal ajanlar içeren kompozisyonlar.
IN2015MU00865A (enExample)
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
NO20092998L (no) Flytende formuleringer, som danner dermal film, for frigjoring av legemidler til huden
BR112013032396A2 (pt) formulações estáveis de aplicações relacionadas à enzima de degradação de ácido hialurônico
ES2531083T3 (es) Formulaciones estables de polipéptidos y usos de las mismas
AR068302A1 (es) Peptidos para vacunas para canceres que expresan antigenos asociados con tumores
PE20131200A1 (es) Composiciones herbicidas solidas con un adyuvante integrado
IN2014MN01470A (enExample)
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
PH12014502778B1 (en) Antibody formulation
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
SG10201901106WA (en) Novel lipids and compositions for the delivery of therapeutics
BRPI0511704A (pt) formulações aquosas com pouca espuma como defensivo para plantas
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
AR081724A1 (es) Composicion herbicida que contiene los hidratos de saflufenacilo y glifosato o glufosinato
TW200733968A (en) Stabilized lanthanum carbonate compositions
MX337458B (es) Una formulacion antiespumante y metodos de elaboracion y uso de la misma.
MX2019003611A (es) Formulaciones novedosas.
EP4249060A3 (en) Liquid pharmaceutical composition of adalimumab
BR112012007842A2 (pt) um copolímero em bloco e composição de poliesteramida com terminação éster e usos dos mesmos

Legal Events

Date Code Title Description
FB Suspension of granting procedure